Full-Time

PET Clinical Application Specialist

West

Updated on 8/23/2026

GE Healthcare

GE Healthcare

1-10 employees

Imaging, monitoring, and healthcare IT solutions

Compensation Overview

$92k - $138k/yr

+ Performance-based cash bonus + Long-term incentives

No H1B Sponsorship

Remote in USA

Hybrid

Must live in or relocate to the listed territory; requires 90%+ travel within the US and Canada.

Bachelor's

Category
Biology & Biotech (1)
Required Skills
Microsoft Windows
Word/Pages/Docs
Excel/Numbers/Sheets
Microsoft Outlook
PowerPoint/Keynote/Slides

Get referred to GE Healthcare

See people who can refer or advise you

Requirements
  • A minimum of 3 years of imaging experience, including at least 3 years of PET modality experience.
  • The candidate must live in or be willing to relocate to the territory covering California, Dallas, Texas, Atlanta, Georgia, Arizona, Nevada, Utah, Colorado, and Idaho.
  • ARRT or equivalent PET modality certification is required.
  • Comfort working in a clinical and patient environment.
  • Willingness and ability to travel extensively, at least 90% of the time, including four to five days per week, overnight stays, weekends, and travel by car, air, and train within the United States and Canada.
  • Proficiency with Windows, Outlook, Word, PowerPoint, Excel, and other computer- and web-based tools.
  • Ability to learn specialized industry-specific software and provide digital education and training solutions.
  • Ability to register with vendor credentialing services used by customer hospitals, including providing immunization records for mumps, measles, rubella, and hepatitis and completing drug testing or screening.
  • For U.S.-based positions, a bachelor's degree from an accredited university or college, or a high school diploma/GED with at least 6 years of experience in the relevant job family or function.
  • Legal authorization to work in the United States.
  • Successful completion of a drug screen, as applicable.
Responsibilities
  • Develop product, clinical, and software knowledge, skills, and competence within the PET modality.
  • Correlate theoretical knowledge with clinical and product information to help clinicians obtain optimal performance from GE Healthcare equipment.
  • Provide pre-sale product clinical evaluations and educational sessions to potential customers.
  • Develop and administer clinical training for end-user personnel in partnership with customers and in alignment with the sales order agreement.
  • Collaborate and coordinate customer training with sales, project management, account management, and other service organization teams.
  • Deliver on-site or remote clinical education to support revenue realization.
  • Complete documentation requirements consistently and on time before, during, and after training.
  • Provide post-installation training and support throughout the product lifecycle.
  • Maintain customer relationships through proactive communication and report relevant product or customer concerns and improvement opportunities to management, field sales, marketing, customer loyalty leads, and technical support.
  • Apply technical expertise, judgment, and analytical thinking to solve straightforward tasks and propose solutions outside set parameters with guidance.
  • Provide informal guidance to new team members.
Desired Qualifications
  • Strong oral and written communication skills.
  • Ability to analyze and resolve problems.
  • Ability to document, plan, market, and execute programs.
  • Established project management skills.

GE Healthcare Systems provides medical technologies and digital infrastructure to improve diagnosis, treatment, and monitoring of patients. Its products include imaging systems, mobile diagnostic devices, patient monitoring tools, and healthcare IT software that work together as hardware, software, and services to support hospitals, clinics, and researchers. The company differentiates itself with a large, integrated ecosystem, strong focus on AI analytics, and a global service network backed by substantial R&D investment. Its goal is to improve patient outcomes and the efficiency of healthcare delivery by enabling accurate diagnoses, effective treatments, and scaled operations.

Company Size

1-10

Company Stage

IPO

Headquarters

Chicago, Illinois

Founded

1892

Get referred to GE Healthcare

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 orders rose 11.1% and backlog hit a record $23.9 billion.
  • August 3, 2026 Invenia ABUS Prime targets dense-breast screening demand and remote reading.
  • Tariff refunds and supply-chain shifts lifted Q2 2026 profits, while 2026 guidance stayed reaffirmed.

What critics are saying

  • Patient Care Solutions fell 13.5% in Q2 2026, and management is reviewing sale options.
  • CFO Jay Saccaro exits August 14, 2026, adding execution risk during the PCS review.
  • Siemens Healthineers and Philips pressure GEHC in imaging; stalled innovation erodes hospital preference.

What makes GE Healthcare unique

  • GE HealthCare combines imaging, pharmaceutical diagnostics, and MIM software across one workflow stack.
  • Its August 2026 ABUS Prime and Allia upgrades monetize installed bases without replacements.
  • FDA-cleared AI tools like ProtégéAI+ 2.0 shorten oncology workflows and deepen switching costs.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Tuition Reimbursement

Relocation Assistance

Company News

Yahoo Finance
Aug 3rd, 2026
GE HealthCare launches Invenia ABUS Prime and StreamVue for breast cancer screening

GE HealthCare has launched Invenia ABUS Prime and ABUS StreamVue, expanding its breast imaging portfolio with solutions for supplemental screening in women with dense breasts. The Invenia ABUS Prime system has been installed at BeSound in Los Angeles, marking one of the first US installations. ABUS StreamVue is a browser-based reading solution enabling remote exam review across imaging networks. The system received FDA 510(k) clearance and CE Marking. Studies show 40% of women have dense breasts, carrying four to six times higher breast cancer risk. Research indicates mammography may miss one-third of cancers in dense breasts. Invenia ABUS Prime features AI-enabled tools including Scan Quality Assessment and can increase scan speed by up to 40%. The AI Assistant has demonstrated a 33% reduction in reading time.

Yahoo Finance
Jul 29th, 2026
GE HealthCare Q2: Orders up 11%, backlog hits record $23.9B amid Patient Care struggles

GE HealthCare Technologies reported second-quarter results with orders rising 11% year-over-year and backlog reaching a record $23.9 billion. Revenue grew 3.5% organically to $5.3 billion, driven by Advanced Imaging Solutions and Pharmaceutical Diagnostics, which posted organic growth of 5% and 14.6% respectively. Patient Care Solutions remained weak, with revenue falling 13.5% due to component shortages and fulfilment problems. Management is reviewing strategic options for the segment, including a potential sale. The company maintained its full-year outlook of 3–4% organic sales growth, adjusted earnings per share of $4.80–$5.00, and approximately $1.6 billion in free cash flow. CFO Jay Saccaro is departing, with George Newcomb serving as interim CFO.

Yahoo Finance
Jul 29th, 2026
GE HealthCare beats profit estimates on imaging demand and $129M tariff refunds

GE HealthCare exceeded Wall Street's second-quarter profit estimates, driven by robust demand for diagnostic and imaging devices and tariff refunds from the Trump administration. The medical device maker reported net income of $561 million, up from $486 million last year, which included $129 million in tariff refunds. Revenue reached $5.30 billion for the quarter ending 30 June, surpassing the estimated $5.26 billion. Sales in imaging devices grew 7.9%, whilst pharmaceutical diagnostics jumped 15.6%. Adjusted earnings per share came in at $1.13, beating analysts' estimate of $1.04. The company's shares rose 12% in premarket trading. However, GE HealthCare noted that geopolitical instability, including Middle East conflicts, negatively affected costs, supply chains and logistics during the quarter.

Yahoo Finance
Jul 29th, 2026
GE HealthCare beats estimates with record orders, shares jump 9%

GE HealthCare Technologies reported second-quarter results that exceeded Wall Street expectations. Adjusted earnings per share reached $1.13, beating the $1.04 consensus estimate, whilst revenue hit $5.3 billion, surpassing the $5.26 billion forecast and marking a 5.7% year-on-year increase. The company delivered record organic orders growth of 11.1% with a book-to-bill ratio of 1.15 times and backlog of $23.9 billion. Organic revenue grew 3.5%, driven by strength in Pharmaceutical Diagnostics and Advanced Imaging Solutions. Patient Care Solutions revenue declined 13.5% year-on-year. Adjusted EBIT margin came in at 14.2%, down 40 basis points from the prior year. Shares jumped 9% premarket following the release. GE HealthCare reaffirmed its full-year guidance, projecting organic revenue growth of 3.0% to 4.0% and adjusted EPS between $4.80 and $5.00.

Fortune
Jul 23rd, 2026
GE's $593B comeback: How CEO Larry Culp pulled off history's greatest turnaround

GE CEO Larry Culp has orchestrated what many industry leaders consider the greatest corporate turnaround in modern business history. When he took over in 2018, GE's market capitalisation stood at $96 billion, down over 80% from its 2000 peak, with $150 billion in crushing debt. Today, the three companies Culp created from GE's breakup — GE Aerospace, GE Vernova, and GE HealthCare — have a combined market value of $689 billion. The trio has delivered annualised returns of roughly 30% since Culp's arrival, double the S&P 500's performance. GE Vernova has jumped over 600% whilst GE Aerospace has risen more than 160%. Culp's approach centred on lean manufacturing principles learnt from the Toyota Production System. He decentralised operations, eliminated three-quarters of central staff positions, and fostered a culture encouraging managers to spotlight problems rather than successes.